
Teneligliptin (20mg) + Metformin (500mg)
Active composition
+1 more active ingredient
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Ecoglip-TM Tablet PR is a combination anti-diabetic medication containing Metformin 500mg and Teneligliptin 20mg, formulated to help manage blood sugar levels in individuals with type 2 diabetes. Metformin works by reducing glucose production in the liver and improving the body’s sensitivity to insulin, while Teneligliptin increases incretin hormone activity to enhance insulin secretion after meals. Together, these ingredients provide effective and balanced blood sugar control throughout the day. The prolonged-release formulation helps maintain stable glucose levels and supports better metabolic control. When used alongside a healthy diet and regular physical activity, Ecoglip-TM Tablet PR helps reduce the risk of diabetes-related complications such as nerve damage, kidney problems, and heart disease when taken as directed by a healthcare professional.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Ecoglip-TM Tablet PR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Ecoglip-TM Tablet PR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Ecoglip-TM Tablet PR should be used with caution in patients with kidney disease. Dose adjustment of Ecoglip-TM Tablet PR may be needed. Please consult your doctor. Use of Ecoglip-TM Tablet PR is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Ecoglip-TM Tablet PR alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Ecoglip-TM Tablet PR is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Ecoglip-TM Tablet PR

Metformin (500mg) + Teneligliptin (20mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Ecoglip-TM Tablet PR is a combination anti-diabetic medication containing Metformin 500mg and Teneligliptin 20mg, formulated to help manage blood sugar levels in individuals with type 2 diabetes. Metformin works by reducing glucose production in the liver and improving the body’s sensitivity to insulin, while Teneligliptin increases incretin hormone activity to enhance insulin secretion after meals. Together, these ingredients provide effective and balanced blood sugar control throughout the day. The prolonged-release formulation helps maintain stable glucose levels and supports better metabolic control. When used alongside a healthy diet and regular physical activity, Ecoglip-TM Tablet PR helps reduce the risk of diabetes-related complications such as nerve damage, kidney problems, and heart disease when taken as directed by a healthcare professional.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Ecoglip-TM Tablet PR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Ecoglip-TM Tablet PR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Ecoglip-TM Tablet PR should be used with caution in patients with kidney disease. Dose adjustment of Ecoglip-TM Tablet PR may be needed. Please consult your doctor. Use of Ecoglip-TM Tablet PR is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Ecoglip-TM Tablet PR alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Ecoglip-TM Tablet PR is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Ecoglip-TM Tablet PR













